Adalimumab is the biosimilar version of Humira®, and the human IgG1 for binding the excess TNFs and inhibiting the cascade inflammation induced thereof. Hence, it served the function to alleviate the inflammatory symptoms by rheumatoid arthritis (RA), and reduces the pain, uncomfort and joint deformities of the one suffered from the repeated inflammation.
Adalimumab is indicated for rheumatoid arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis.
The cell line development and similarity study of adalimumab are completed. We are looking for partner for co-development or licensee for marketing and sales.